GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...
3hon MSN
Adjusted EPS guidance for FY2025 was updated to approximately $4.5, driven by lower interest costs and strong financial performance. The company anticipates Q4 2025 revenue of approximately $290 ...
Zacks Equity Research shares Kratos Defense & Security Solutions KTOS as the Bull of the Day and GSK PLC GSK as the Bear of ...
The offering, Consumer-Directed Health, will provide employers and individuals an array of products and services that allow ...
Shanon and William Schmidtknecht, of Poynette, say their 22-year-old son Cole was told the cost had jumped from $66 to $539 ...
Civic Science on MSN2h
GLP-1 Trends by CivicScience: GLP-1 Users Foresee Long-Term Use, Spending More on Clothing and Groceries, Plus MoreThis is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback